Researchers dig through health records to map rare heart disease

NCT ID NCT07494656

Not yet recruiting Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This study looks back at existing German health insurance records to better understand ATTR-CM, a rare and serious heart condition. Researchers will analyze data from people diagnosed between 2020 and 2022 to learn about their survival rates, hospital visits, and how common the disease is. No new treatments are being tested; the goal is to gather real-world information to improve future care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.